FDA approves new treatment for sickle cell disease

On July 7, the U.S. Food and Drug Administration (FDA) approved Endari (L-glutamine oral powder) for patients age 5 years and older with sickle cell disease to reduce severe complications associated with the disorder. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here